This week was loaded with earnings releases of many large drugmakers. Novo Nordisk NVO, Merck MRK, Pfizer PFE, Eli Lilly LLY, ...

Bristol Myers Squibb beat Q4 estimates with $12.34 billion revenue and $1.67 EPS. 2025 guidance lags expectations amid ...

In a report released yesterday, Umer Raffat from Evercore ISI maintained a Buy rating on Merck & Company (MRK – Research Report). The ...

Jefferies analyst Akash Tewari maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on February 3 and set a price target of ...

Investors have taken to punishing pharma companies that appear unable to gauge demand for their top products. Consider Pfizer. The company’s inability to accurately project demand for its Covid-19 ...

Merck's combination of a wide lineup of high-margin drugs and a pipeline of new drugs should ensure strong returns on invested capital over the long term. Further, following the divestment of the ...

As the nation kicks off Black History Month, a look into the industry shows there is a significant lack of Black leaders.

Sales of Eylea, which the company co-developed with Bayer (DE:BAYA), rose 2% to $1.495 billion. Sales of the higher-dose, longer-lasting formulation Eylea HD rose 148% to $305 million in the U.S., ...

A woman's hands star in a Lilly spot, shown playing key role in activities like gardening -- and discovering a lump in her ...

Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...

Idexx Laboratories posted strong Q4 earnings, beating estimates with 10% EPS growth. 2025 guidance reflects up to 7% revenue growth and $1.5 billion in buybacks.